Announcement • Jun 22
InterCure Ltd. announced that it expects to receive ILS 21.711643 million in funding from Bennu Pharma Fund Ltd and other investors. InterCure Ltd entered into a binding term sheet for a private placement to issue 7,895,143 units at an issue price of ILS 2.75 for the proceeds of ILS 21,711,643.25 on June 22, 2026. Each unit consisting of one ordinary share, no par value, of the Company (an “Ordinary Share”) and one warrant to purchase one Ordinary Share. Each warrant will be exercisable for a period of five years from the date of issuance at an exercise price of ILS 4.125 per Ordinary Share. Transaction is subject to shareholder approval. The Private Placement will be conducted without an underwriter, placement agent, broker or dealer. The funding includes investments commitments from key shareholders of the Company, including the Company’s CEO Alexander Rabinovitch, as well as leading pharma-focused hedge funds, including Bennu Pharma Fund Ltd., managed by Mr. Ori Hershkovitz. New Risk • May 30
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Israeli stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). Earnings have declined by 48% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (16% increase in shares outstanding). Market cap is less than US$100m (₪196.3m market cap, or US$69.6m). Reported Earnings • May 05
Full year 2025 earnings released: ₪0.66 loss per share (vs ₪1.48 loss in FY 2024) Full year 2025 results: ₪0.66 loss per share (improved from ₪1.48 loss in FY 2024). Revenue: ₪270.2m (up 13% from FY 2024). Net loss: ₪35.7m (loss narrowed 47% from FY 2024). Over the last 3 years on average, earnings per share has fallen by 59% per year but the company’s share price has only fallen by 33% per year, which means it has not declined as severely as earnings. 
